← Back to Search

Monoclonal Antibodies

Radioimmunotherapy for Non-Hodgkin's Lymphoma

N/A

Waitlist Available

Research Sponsored by Corixa Corporation

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients must have previously responded (PR, CCR, or CR) with a duration of response of at least 3 months to Iodine-131 Anti-B1 Antibody therapy. The patient's disease must have progressed following the response to Iodine-131 Anti-B1 Antibody therapy

Patients must have evidence that their tumor tissue expresses the CD20 antigen

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial will allow NHL patients who responded to Iodine-131 Anti-B1 Antibody therapy to be retreatment with the same therapy.

Who is the study for?

This trial is for patients with non-Hodgkin's B-cell lymphoma who previously had a positive response to Iodine-131 Anti-B1 Antibody therapy. They must have measurable disease, good performance status, adequate organ function, and no serious illnesses like heart disease or active infections. Pregnant or breastfeeding individuals are excluded.Check my eligibility

What is being tested?

The study tests the safety and effectiveness of retreating non-Hodgkin's lymphoma patients with Iodine-131 Anti-B1 Antibody if they've responded well before but their cancer has progressed. It checks if reusing this treatment offers any benefit.See study design

What are the potential side effects?

Potential side effects may include allergic reactions (not related to IV contrast materials), effects on blood counts requiring transfusions or growth factors, kidney and liver function changes, and possibly increased risk of infection due to weakened immune defenses.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My cancer responded to Iodine-131 Anti-B1 therapy but has since worsened.

Select...

My tumor tests positive for the CD20 protein.

Select...

My initial diagnosis was non-Hodgkin's B-cell lymphoma.

Select...

I can care for myself and expect to live at least 3 more months.

Select...

My blood tests show enough white cells and platelets without needing transfusions or other help.

Select...

I have a tumor that is at least 2 x 2 cm large.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

0 / 6Eligibility criteria met

Find a Location

Who is running the clinical trial?

Corixa CorporationLead Sponsor

9 Previous Clinical Trials

590 Total Patients Enrolled

GlaxoSmithKlineIndustry Sponsor

4,750 Previous Clinical Trials

8,067,452 Total Patients Enrolled

Media Library

Iodine-131 Anti-B1 Antibody (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT00022893 — N/A

Non-Hodgkin's Lymphoma Research Study Groups:

Non-Hodgkin's Lymphoma Clinical Trial 2023: Iodine-131 Anti-B1 Antibody Highlights & Side Effects. Trial Name: NCT00022893 — N/A

Iodine-131 Anti-B1 Antibody (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00022893 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the geographical spread of this experiment?

"Currently, this clinical trial is enrolling patients from 4 distinct medical centres. These are located in Chicago, Ann Arbor and Palo Alto alongside several other places. It may be prudent to choose the closest clinic so that travelling between appointments is not a hassle."

Answered by AI